Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug Use-Results Survey of OPDIVO in Malignant Pleural Mesothelioma After Chemotherapy
jRCT2011230029Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in pleural mesothelioma, sponsored by Ono Pharmaceutical. Primary endpoints: Safety – adverse drug reactions and infections, Safety – factors affecting safety and 1 more. Started Dec 2018; status: completed.
02
Drugs
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on jRCT2011230029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011230029.